Education regarding treatment and supportive care issues is required to bridge the gap in AYA cancer care and improve outcomes in this population.

By staying up-to-date on new approaches and options for neoadjuvant/adjuvant systemic therapy, clinicians should be able to provide appropriate care using a shared decision-making process with the patient, taking into account patient and disease characteristics, including risk of recurrence, and weighing the potential benefits and risks of each option. In addition, it is important for clinicians to be aware of new supportive care interventions available to improve the quality of life of patients.

Considerable progress has been made in understanding which patients will benefit from radiation therapy and ways to administer treatment that maximize clinical benefit while minimizing toxicity. However, many controversies exist as well.  In order to define clinical situations that require appropriate locoregional therapies and use the right approach, clinicians need to stay current on the updates and controversies.

Genetic testing should be considered in individuals for whom there is a personal or family history suggesting susceptibility to hereditary cancer and for whom results can potentially impact risk management and treatment.

This education activity will help outline the existing breast cancer disparities, as well as highlight methods/strategies that may help narrow the racial/survival gap and provide better cancer care to all.

The goal of this activity is to improve the knowledge and competence of learners to apply practice-changing clinical data and expert recommendations to optimize clinical outcomes for their patients with HER2-positive breast cancer.

Triple-negative breast cancer continues to be labeled with a poor prognosis secondary to the fact that it tends to be more aggressive and poses a greater risk of recurrence. Because it lacks the receptors that many drugs have been designed to target, the standard of practices remains chemotherapy. Therefore, research has been focused on trying to identify other therapeutic targets for which we already have agents or are currently developing agents.

Staying up-to-date with the available treatment options is important for health care professionals to integrate new evidence-based data into their clinical practice, and being familiar with the toxicity profile is important to optimize patient outcomes.